Pfizer | November 10, 2020

Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examination and lead the primary interval investigation at least 62 cases. Upon the finish of those conversations, the evaluable case check arrived at 94 and the DMC played out its first examination on all cases.

The case split between inoculated people and the individuals who got the fake treatment shows an immunization viability rate above 90%, at seven days after the subsequent portion. This implies that insurance is accomplished 28 days after the inception of the immunization, which comprises of a 2-portion plan. As the investigation proceeds, the last antibody adequacy rate may shift. The DMC has not detailed any genuine security concerns and prescribes that the examination keeps on gathering extra wellbeing and viability information as arranged. The information will be talked about with administrative specialists around the world.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech Co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”

The Phase 3 clinical preliminary of BNT162b2 started on July 27 and has selected 43,538 members to date, 38,955 of whom have gotten a second portion of the immunization competitor as of November 8, 2020. Roughly 42% of worldwide members and 30% of U.S. members have racially and ethnically assorted foundations. The preliminary is proceeding to select and is relied upon to proceed through the last examination when an aggregate of 164 affirmed COVID-19 cases have gathered. The investigation likewise will assess the potential for the antibody possibility to give insurance against COVID-19 in the individuals who have had earlier presentation to SARS-CoV-2, just as immunization avoidance against serious COVID-19 infection. Notwithstanding the essential adequacy endpoints assessing affirmed COVID-19 cases accumulating from seven days after the subsequent portion, the last investigation currently will incorporate, with the endorsement of the FDA, new auxiliary endpoints assessing viability dependent on cases building 14 days after the subsequent portion also. The organizations accept that the expansion of these optional endpoints will help adjust information over all COVID-19 antibody reads and consider cross-preliminary learnings and correlations between these novel immunization stages.

Pfizer and BioNTech are proceeding to gather security information and presently gauge that a middle of two months of wellbeing information following the second (and last) portion of the antibody up-and-comer – the measure of security information indicated by the FDA in its direction for likely Emergency Use Authorization – will be accessible by the third seven day stretch of November. Moreover, members will keep on being checked for long haul assurance and wellbeing for an extra two years after their subsequent portion.

Alongside the viability information created from the clinical preliminary, Pfizer and BioNTech are attempting to set up the important wellbeing and assembling information to submit to the FDA to exhibit the security and nature of the antibody item delivered. In view of gracefully projections, we hope to flexibly internationally up to 50 million antibody portions in 2020 and fabricate up to 1.3 billion dosages in 2021. Pfizer and BioNTech plan to submit information from the full Phase 3 preliminary for logical friend survey distribution.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Soaring drug development costs, patent expiration, and reduction in the number of blockbuster drugs are driving pharma companies to look at IT-enabled productivity.


Soaring drug development costs, patent expiration, and reduction in the number of blockbuster drugs are driving pharma companies to look at IT-enabled productivity.

Related News


Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions

Charles River Laboratories International, Inc. and Valo Health, LLC, | January 20, 2022

Charles River Laboratories International, Inc. and Valo Health, LLC, the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development process, today announced the formation of a multiyear strategic partnership. This agreement will combine Valo’s Opal Computational Platform with Charles River’s drug discovery and development capabilities to offer a new transformative, AI-enabled drug discovery and development platform. Recognizing the challenges of preclinical drug discovery, from high costs, time, and attrition rates, Valo and Charles River have joined forces to create enhanced drug discovery solutions that aim to transform the entire preclinical drug discovery process. Valo and Charles River intend to create and deliver offerings that produce preclinical assets with key performance characteristics optimized for client preferences. The partnership’s combined offerings will utilize Valo’s Opal Platform for small molecule development, which leverages a “closed-loop” in silico-experimental platform that rapidly iterates using program data to identify novel compounds, and leverages Charles River’s capabilities in all aspects of discovery optimization, including medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission. The combination of Valo’s scientific innovation and deep technological expertise with Charles River’s end-to-end portfolio and industry-leading scientific bench has the potential to significantly accelerate a client’s discovery and development efforts by integrating data and compute to streamline and de-risk experimental science, enabling a faster and more effective process from de novo molecule design through lead optimization. The combined offering will be launched in the first half of 2022 and will be available exclusively from Charles River. About Valo Health Valo Health, LLC is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence (“AI”) computation. As a digitally native company, Valo aims to full integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Read More


Narrativa Raises $1.3M to Help Pharma Companies Accelerate the FDA Drug Approval Process

Narrativa | May 19, 2021

Narrativa, which has developed an artificial intelligence (AI) medical writing platform to assist pharmaceutical firms in speeding up drug approval and lowering overall compliance costs, recently completed a $1.3 million funding round. The Los Angeles-based firm currently uses its SaaS platform to automate the production of Clinical Study Reports (CSRs) and other regulatory reports for several pharmaceutical firms and other clinical research organizations (CROs). The AI-writing assistant platform utilizes advanced Natural Language Generation (NLG) to process millions of data points from clinical trials and generate readable and understandable written medical narratives, improving accuracy and minimizing the time and expense of producing critical (and time-consuming) regulatory documents. "The pharma industry has evolved as a result of the availability and quality of data from clinical trials, with the most significant impact on drug discovery. To detect trends, test hypotheses, and understand the effectiveness of treatments, pharmaceutical firms have often focused on empirical data. It's time to put artificial intelligence to work assisting medical authors in the development of regulatory documents "Narrativa's founder and CEO, David Llorente, says. Pharmaceutical firms spend more than $1.5 billion on regulatory documentation, and it may take up to a year to complete the paperwork for FDA approval of a new drug. The amount of time taken on regulatory documentation significantly lengthens the time it takes for new drugs to reach the market. About Narrativa Narrativa was established in 2015 with the idea that technology should be used to positively transform the world. Narrativa, named one of the most important companies in the field of NLG by Samsung, helps companies expand by anticipating trends and converting data into the human language in real-time. Narrativa creates automated content in a variety of areas, including finance, pharmaceuticals, insurance, media, and gaming, using its artificial intelligence system and machine learning experience.

Read More


Prescryptive Health Launches Comprehensive Pharmacy Management Platform to Expand the Scope of Community Pharmacists

Prescryptive Health | October 06, 2021

Healthcare technology company Prescryptive Health today announced that MyRx PRO is now operational nationwide. The pharmacy management platform allows pharmacists to digitize their business with new revenue opportunities through profitable clinical services and a deeper patient engagement experience. Today we change the course of the community pharmacist, by empowering them to expand their business and meet new customers through new services, all on our secure platform. Pharmacists are central to community health, and we are proud to offer a system to help them transform for the digital age. - Chris Blackley, CEO of Prescryptive Health At the core of MyRx PRO are turn-key clinical services, which build in patient engagement, inventory management, reporting, and billing all on one platform. This includes critical COVID-19 care—testing, vaccinations, and monoclonal antibody treatment—and flu services for the ongoing public health crisis. MyRx PRO pharmacists already on the platform had a lift in annual revenue up to 25%; by offering relevant services, pharmacists can grow their business while providing the healthcare needed in their local communities. New patients find these services through Prescryptive's patient-friendly mobile solution, I'm getting new patients at my counter every day thanks to Prescryptive, MyRx PRO allows me to offer more services efficiently so I can focus on what matters most: patient care. - Vincent Chiffy, owner of Parkway Drugs in Utica, NY. MyRx PRO also features SmartPRICE™ with AI-driven intelligent pricing capabilities and a solution for cash-paying customers. Unlike popular cash discount cards, SmartPRICE™ saves patients up to 80% on prescriptions without exorbitant fees charged to local pharmacies by third parties. MyRx PRO is available nationwide today, with new clinical services added continually. About Prescryptive Health Prescryptive Health is a healthcare technology company delivering solutions that empower consumers. Prescryptive's secure, mobile-first products connect consumers, pharmacists, and employers, ultimately providing people with the information they need to make informed decisions and take control of their health.

Read More